D9Z.F · Clínica Baviera, S.A

-

Please sign in to comment on D9Z.F

1 Comment

Admin

3 years, 7 months ago

Clínica Baviera, S.A is currently in a long term uptrend where the price is trading 17.6% above its 200 day moving average.

From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.

Clínica Baviera, S.A's total revenue sank by 6.4% to $33M since the same quarter in the previous year.

Its net income has increased by 12.3% to $5M since the same quarter in the previous year.

Finally, its free cash flow grew by 150.2% to $11M since the same quarter in the previous year.

Based on the above factors, Clínica Baviera, S.A gets an overall score of 4/5.

Industry	Diagnostics & Research
Sector	Healthcare
ISIN	ES0119037010
CurrencyCode	EUR
Exchange	F

Target Price	None
Beta	0.51
Dividend Yield	5.5%
PE Ratio	10.22
Market Cap	307M

ABOUT

Clínica Baviera, S.A

Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, vías lagrimales, and oculoplasty treatments. It operates approximately 90 centers in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.

D9Z.F · Clínica Baviera, S.A

-

Clínica Baviera, S.A

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Clínica Baviera, S.A using a moving average strategy